A Look At The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Key Insights
- Using the 2 Stage Free Cash Flow to Equity, BioGaia fair value estimate is kr91.40
- With kr97.30 share price, BioGaia appears to be trading close to its estimated fair value
- Peers of BioGaia are currently trading on average at a 21% discount
Does the April share price for BioGaia AB (publ) (STO:BIOG B) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to today's value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.
Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
See our latest analysis for BioGaia
Crunching The Numbers
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) estimate
2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | |
Levered FCF (SEK, Millions) | kr341.4m | kr374.3m | kr400.2m | kr420.1m | kr435.4m | kr447.1m | kr456.2m | kr463.4m | kr469.3m | kr474.1m |
Growth Rate Estimate Source | Est @ 13.57% | Est @ 9.65% | Est @ 6.91% | Est @ 4.98% | Est @ 3.64% | Est @ 2.70% | Est @ 2.04% | Est @ 1.58% | Est @ 1.25% | Est @ 1.03% |
Present Value (SEK, Millions) Discounted @ 5.3% | kr324 | kr338 | kr343 | kr342 | kr337 | kr329 | kr319 | kr308 | kr296 | kr284 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = kr3.2b
After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (0.5%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 5.3%.
Terminal Value (TV)= FCF2032 × (1 + g) ÷ (r – g) = kr474m× (1 + 0.5%) ÷ (5.3%– 0.5%) = kr10b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= kr10b÷ ( 1 + 5.3%)10= kr6.0b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is kr9.2b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of kr97.3, the company appears around fair value at the time of writing. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.
Important Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at BioGaia as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 5.3%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for BioGaia
- Earnings growth over the past year exceeded the industry.
- Currently debt free.
- Dividend is low compared to the top 25% of dividend payers in the Biotechs market.
- Current share price is above our estimate of fair value.
- BIOG B's financial characteristics indicate limited near-term opportunities for shareholders.
- Dividends are not covered by cash flow.
Moving On:
Whilst important, the DCF calculation shouldn't be the only metric you look at when researching a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For BioGaia, there are three pertinent items you should further research:
- Risks: You should be aware of the 2 warning signs for BioGaia we've uncovered before considering an investment in the company.
- Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for BIOG B's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every Swedish stock every day, so if you want to find the intrinsic value of any other stock just search here.
Valuation is complex, but we're here to simplify it.
Discover if BioGaia might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:BIOG B
Flawless balance sheet with reasonable growth potential and pays a dividend.